The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib

W. C. Maddrey, C. J. Maurath, K. M. Verburg, G. S. Geis

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associated with the potential for hepatotoxicity. This article presents an analysis of the hepatic effects of celecoxib in 14 controlled studies of patients with arthritis (2 to 24 weeks' duration), in a long-term, open-label safety study (as long as 2 years), in 11 studies of patients receiving treatment for pain after oral or orthopedic surgery (up to 5 days' duration), and in five pharmacology studies. The overall incidence of hepatic adverse events in arthritis patients receiving celecoxib was similar to that for placebo but significantly lower than in the combined group of patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). The most commonly reported hepatic adverse events were elevations in liver transaminase levels, most of which occurred in patients receiving diclofenac. Similarly, clinically significant elevations of transaminase levels occurred more frequently with NSAIDs than with celecoxib. A pharmacology study performed in patients with mild or moderate hepatic impairment showed that celecoxib did not produce any clinically relevant changes from baseline in creatinine clearance, alanine amino-transferase, or bilirubin values in these settings. In the four interaction studies performed with drugs metabolized in the liver, none of the adverse events was hepatic in nature, and no clinically relevant liver function test abnormalities occurred. In conclusion, this analysis suggests that celecoxib has a very low potential for hepatic toxicity, even after exposures of as long as 2 years at therapeutic doses.

Original languageEnglish (US)
Pages (from-to)153-158
Number of pages6
JournalAmerican Journal of Therapeutics
Volume7
Issue number3
StatePublished - 2000

Fingerprint

Celecoxib
Cyclooxygenase 2 Inhibitors
Safety
Liver
Transaminases
Arthritis
Anti-Inflammatory Agents
Pharmaceutical Preparations
Pharmacology
Cyclooxygenase 1
Oral Surgery
Diclofenac
Liver Function Tests
Transferases
Bilirubin
Osteoarthritis
Alanine

Keywords

  • Celecoxib
  • COX-2 inhibitors
  • Hepatic toxicity
  • Nonsteroidal anti-inflammatory drugs

ASJC Scopus subject areas

  • Pharmacology

Cite this

The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. / Maddrey, W. C.; Maurath, C. J.; Verburg, K. M.; Geis, G. S.

In: American Journal of Therapeutics, Vol. 7, No. 3, 2000, p. 153-158.

Research output: Contribution to journalArticle

Maddrey, W. C. ; Maurath, C. J. ; Verburg, K. M. ; Geis, G. S. / The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib. In: American Journal of Therapeutics. 2000 ; Vol. 7, No. 3. pp. 153-158.
@article{8409dabee2e240b7ad3b2822bea7e3d1,
title = "The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib",
abstract = "Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associated with the potential for hepatotoxicity. This article presents an analysis of the hepatic effects of celecoxib in 14 controlled studies of patients with arthritis (2 to 24 weeks' duration), in a long-term, open-label safety study (as long as 2 years), in 11 studies of patients receiving treatment for pain after oral or orthopedic surgery (up to 5 days' duration), and in five pharmacology studies. The overall incidence of hepatic adverse events in arthritis patients receiving celecoxib was similar to that for placebo but significantly lower than in the combined group of patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). The most commonly reported hepatic adverse events were elevations in liver transaminase levels, most of which occurred in patients receiving diclofenac. Similarly, clinically significant elevations of transaminase levels occurred more frequently with NSAIDs than with celecoxib. A pharmacology study performed in patients with mild or moderate hepatic impairment showed that celecoxib did not produce any clinically relevant changes from baseline in creatinine clearance, alanine amino-transferase, or bilirubin values in these settings. In the four interaction studies performed with drugs metabolized in the liver, none of the adverse events was hepatic in nature, and no clinically relevant liver function test abnormalities occurred. In conclusion, this analysis suggests that celecoxib has a very low potential for hepatic toxicity, even after exposures of as long as 2 years at therapeutic doses.",
keywords = "Celecoxib, COX-2 inhibitors, Hepatic toxicity, Nonsteroidal anti-inflammatory drugs",
author = "Maddrey, {W. C.} and Maurath, {C. J.} and Verburg, {K. M.} and Geis, {G. S.}",
year = "2000",
language = "English (US)",
volume = "7",
pages = "153--158",
journal = "American Journal of Therapeutics",
issn = "1075-2765",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - The hepatic safety and tolerability of the novel cyclooxygenase-2 inhibitor celecoxib

AU - Maddrey, W. C.

AU - Maurath, C. J.

AU - Verburg, K. M.

AU - Geis, G. S.

PY - 2000

Y1 - 2000

N2 - Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associated with the potential for hepatotoxicity. This article presents an analysis of the hepatic effects of celecoxib in 14 controlled studies of patients with arthritis (2 to 24 weeks' duration), in a long-term, open-label safety study (as long as 2 years), in 11 studies of patients receiving treatment for pain after oral or orthopedic surgery (up to 5 days' duration), and in five pharmacology studies. The overall incidence of hepatic adverse events in arthritis patients receiving celecoxib was similar to that for placebo but significantly lower than in the combined group of patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). The most commonly reported hepatic adverse events were elevations in liver transaminase levels, most of which occurred in patients receiving diclofenac. Similarly, clinically significant elevations of transaminase levels occurred more frequently with NSAIDs than with celecoxib. A pharmacology study performed in patients with mild or moderate hepatic impairment showed that celecoxib did not produce any clinically relevant changes from baseline in creatinine clearance, alanine amino-transferase, or bilirubin values in these settings. In the four interaction studies performed with drugs metabolized in the liver, none of the adverse events was hepatic in nature, and no clinically relevant liver function test abnormalities occurred. In conclusion, this analysis suggests that celecoxib has a very low potential for hepatic toxicity, even after exposures of as long as 2 years at therapeutic doses.

AB - Celecoxib is a cyclooxygenase- (COX)-1-sparing inhibitor of COX-2 that is indicated for the treatment of osteoarthritis and rheumatoid arthritis. Many agents used for treating these diseases, both symptom-modifying and disease-modifying, are associated with the potential for hepatotoxicity. This article presents an analysis of the hepatic effects of celecoxib in 14 controlled studies of patients with arthritis (2 to 24 weeks' duration), in a long-term, open-label safety study (as long as 2 years), in 11 studies of patients receiving treatment for pain after oral or orthopedic surgery (up to 5 days' duration), and in five pharmacology studies. The overall incidence of hepatic adverse events in arthritis patients receiving celecoxib was similar to that for placebo but significantly lower than in the combined group of patients receiving nonsteroidal anti-inflammatory drugs (NSAIDs). The most commonly reported hepatic adverse events were elevations in liver transaminase levels, most of which occurred in patients receiving diclofenac. Similarly, clinically significant elevations of transaminase levels occurred more frequently with NSAIDs than with celecoxib. A pharmacology study performed in patients with mild or moderate hepatic impairment showed that celecoxib did not produce any clinically relevant changes from baseline in creatinine clearance, alanine amino-transferase, or bilirubin values in these settings. In the four interaction studies performed with drugs metabolized in the liver, none of the adverse events was hepatic in nature, and no clinically relevant liver function test abnormalities occurred. In conclusion, this analysis suggests that celecoxib has a very low potential for hepatic toxicity, even after exposures of as long as 2 years at therapeutic doses.

KW - Celecoxib

KW - COX-2 inhibitors

KW - Hepatic toxicity

KW - Nonsteroidal anti-inflammatory drugs

UR - http://www.scopus.com/inward/record.url?scp=0034189399&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034189399&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 153

EP - 158

JO - American Journal of Therapeutics

JF - American Journal of Therapeutics

SN - 1075-2765

IS - 3

ER -